JP2019142930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019142930A5 JP2019142930A5 JP2019082794A JP2019082794A JP2019142930A5 JP 2019142930 A5 JP2019142930 A5 JP 2019142930A5 JP 2019082794 A JP2019082794 A JP 2019082794A JP 2019082794 A JP2019082794 A JP 2019082794A JP 2019142930 A5 JP2019142930 A5 JP 2019142930A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- pyridin
- trifluoromethyl
- amino
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 claims 19
- 238000000634 powder X-ray diffraction Methods 0.000 claims 15
- URUBZXVIOILFLM-UHFFFAOYSA-N CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O Chemical compound CC(C)(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F)OS(C)(=O)=O URUBZXVIOILFLM-UHFFFAOYSA-N 0.000 claims 12
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 6
- 201000005787 hematologic cancer Diseases 0.000 claims 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 230000000750 progressive effect Effects 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 206010008583 Chloroma Diseases 0.000 claims 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000005987 myeloid sarcoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021123814A JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361861884P | 2013-08-02 | 2013-08-02 | |
| US61/861,884 | 2013-08-02 | ||
| PCT/CN2013/081170 WO2015018060A1 (en) | 2013-08-09 | 2013-08-09 | Crystalline forms of therapeutically active compounds and use thereof |
| CNPCT/CN2013/081170 | 2013-08-09 | ||
| US201461939098P | 2014-02-12 | 2014-02-12 | |
| US61/939,098 | 2014-02-12 | ||
| US201461975448P | 2014-04-04 | 2014-04-04 | |
| US61/975,448 | 2014-04-04 | ||
| US201462011948P | 2014-06-13 | 2014-06-13 | |
| US62/011,948 | 2014-06-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Division JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021123814A Division JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019142930A JP2019142930A (ja) | 2019-08-29 |
| JP2019142930A5 true JP2019142930A5 (https=) | 2019-10-10 |
Family
ID=52432592
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Active JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
| JP2019082794A Withdrawn JP2019142930A (ja) | 2013-08-02 | 2019-04-24 | 治療活性のある化合物及びその使用方法 |
| JP2021123814A Pending JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531940A Active JP6742905B2 (ja) | 2013-08-02 | 2014-08-01 | 治療活性のある化合物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021123814A Pending JP2021176893A (ja) | 2013-08-02 | 2021-07-29 | 治療活性のある化合物及びその使用方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US9738625B2 (https=) |
| EP (3) | EP3027193A4 (https=) |
| JP (3) | JP6742905B2 (https=) |
| CN (3) | CN110386922A (https=) |
| AU (2) | AU2014295938B2 (https=) |
| BR (1) | BR112016002287A2 (https=) |
| CA (1) | CA2919382A1 (https=) |
| CL (2) | CL2016000263A1 (https=) |
| EA (1) | EA030428B1 (https=) |
| ES (1) | ES2886211T3 (https=) |
| IL (2) | IL243833A0 (https=) |
| MX (2) | MX389250B (https=) |
| MY (1) | MY177994A (https=) |
| NI (1) | NI201600022A (https=) |
| PE (1) | PE20160840A1 (https=) |
| PH (1) | PH12016500164B1 (https=) |
| SA (1) | SA516370523B1 (https=) |
| SG (2) | SG10201709187TA (https=) |
| TW (2) | TWI666208B (https=) |
| UA (1) | UA121021C2 (https=) |
| WO (1) | WO2015017821A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) * | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| AU2015324158A1 (en) | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| WO2016177347A1 (en) * | 2015-05-07 | 2016-11-10 | Teligene Ltd | Heterocyclic compounds as idh2 inhibitors |
| TWI722004B (zh) | 2015-07-30 | 2021-03-21 | 大陸商正大天晴藥業集團股份有限公司 | 1,3,5-三嗪衍生物及其使用方法 |
| CA2993615A1 (en) | 2015-08-05 | 2017-02-09 | Agios Pharmaceuticals, Inc. | Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines |
| CN108366980A (zh) | 2015-10-15 | 2018-08-03 | 安吉奥斯医药品有限公司 | 用于治疗恶性肿瘤的组合疗法 |
| US10695352B2 (en) * | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| US9688659B2 (en) * | 2015-10-21 | 2017-06-27 | NeuForm Pharmaceuticals, Inc. | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof |
| IL298663A (en) * | 2015-12-04 | 2023-01-01 | Agios Pharmaceuticals Inc | Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| ES2912909T3 (es) | 2016-02-26 | 2022-05-30 | Celgene Corp | Enasidenib para su uso en el tratamiento de la leucemia mieloide aguda recidivante o refractaria |
| EP3493809B1 (en) | 2016-08-03 | 2023-08-23 | Celgene Corporation | Enasidenib for treatment of myelodysplastic syndrome |
| JP7093764B2 (ja) * | 2016-08-03 | 2022-06-30 | セルジーン コーポレイション | 骨髄異形成症候群の治療方法 |
| MX392941B (es) | 2016-09-07 | 2025-03-24 | Celgene Corp | Composiciones para comprimidos. |
| WO2018133856A1 (zh) * | 2017-01-22 | 2018-07-26 | 正大天晴药业集团股份有限公司 | 1，3，5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途 |
| WO2018204787A1 (en) | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| EP4201399A3 (en) | 2017-06-30 | 2023-08-09 | Celgene Corporation | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| WO2021097160A1 (en) | 2019-11-14 | 2021-05-20 | Celgene Corporation | Pediatric formulations for treatment of cancer |
| CN114773320A (zh) * | 2022-05-29 | 2022-07-22 | 重庆医科大学 | 1,3,5-三嗪化合物及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| JPS58186682A (ja) | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| EP0466647B1 (de) | 1990-07-12 | 1995-11-29 | Ciba-Geigy Ag | Verfahren zur photochemischen und thermischen Stabilisierung von Polyamid-Fasermaterialien |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| WO2000075129A1 (en) | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| EP1546121B1 (en) | 2002-07-18 | 2012-08-29 | Janssen Pharmaceutica NV | Substituted triazine kinase inhibitors |
| JP5450381B2 (ja) * | 2007-04-30 | 2014-03-26 | プロメティック・バイオサイエンスィズ・インコーポレーテッド | 化合物、そのような化合物を含有する組成物、及びそのような化合物を用いるがん及び自己免疫疾患の治療法 |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| KR101460095B1 (ko) * | 2009-06-08 | 2014-11-10 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| US8486939B2 (en) * | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| NZ627096A (en) * | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| WO2013133367A1 (ja) | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| AU2015324158A1 (en) * | 2014-09-29 | 2017-04-13 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
-
2014
- 2014-08-01 TW TW103126335A patent/TWI666208B/zh active
- 2014-08-01 MX MX2016001361A patent/MX389250B/es unknown
- 2014-08-01 AU AU2014295938A patent/AU2014295938B2/en active Active
- 2014-08-01 UA UAA201601999A patent/UA121021C2/uk unknown
- 2014-08-01 EP EP14832505.3A patent/EP3027193A4/en not_active Withdrawn
- 2014-08-01 SG SG10201709187TA patent/SG10201709187TA/en unknown
- 2014-08-01 EP EP19177845.5A patent/EP3566706B1/en active Active
- 2014-08-01 MX MX2020011397A patent/MX394658B/es unknown
- 2014-08-01 TW TW108110624A patent/TWI701242B/zh active
- 2014-08-01 ES ES19177845T patent/ES2886211T3/es active Active
- 2014-08-01 WO PCT/US2014/049469 patent/WO2015017821A2/en not_active Ceased
- 2014-08-01 EP EP21178745.2A patent/EP3932408A1/en not_active Withdrawn
- 2014-08-01 US US14/909,451 patent/US9738625B2/en active Active
- 2014-08-01 SG SG11201600479WA patent/SG11201600479WA/en unknown
- 2014-08-01 EA EA201690322A patent/EA030428B1/ru not_active IP Right Cessation
- 2014-08-01 MY MYPI2016700311A patent/MY177994A/en unknown
- 2014-08-01 BR BR112016002287A patent/BR112016002287A2/pt not_active Application Discontinuation
- 2014-08-01 PH PH1/2016/500164A patent/PH12016500164B1/en unknown
- 2014-08-01 CN CN201910708167.6A patent/CN110386922A/zh active Pending
- 2014-08-01 CN CN201480053796.5A patent/CN105916507A/zh active Pending
- 2014-08-01 JP JP2016531940A patent/JP6742905B2/ja active Active
- 2014-08-01 PE PE2016000214A patent/PE20160840A1/es not_active Application Discontinuation
- 2014-08-01 CN CN201910707312.9A patent/CN110372670B/zh active Active
- 2014-08-01 CA CA2919382A patent/CA2919382A1/en not_active Abandoned
-
2016
- 2016-01-28 IL IL243833A patent/IL243833A0/en unknown
- 2016-02-01 SA SA516370523A patent/SA516370523B1/ar unknown
- 2016-02-01 NI NI201600022A patent/NI201600022A/es unknown
- 2016-02-02 CL CL2016000263A patent/CL2016000263A1/es unknown
-
2017
- 2017-07-13 US US15/649,551 patent/US10093654B2/en active Active
- 2017-09-04 CL CL2017002240A patent/CL2017002240A1/es unknown
-
2018
- 2018-09-04 US US16/121,483 patent/US10730854B2/en active Active
- 2018-10-10 AU AU2018247242A patent/AU2018247242B2/en active Active
-
2019
- 2019-04-24 JP JP2019082794A patent/JP2019142930A/ja not_active Withdrawn
- 2019-10-31 IL IL270347A patent/IL270347B/en unknown
-
2020
- 2020-06-29 US US16/915,936 patent/US20210155603A1/en not_active Abandoned
-
2021
- 2021-07-29 JP JP2021123814A patent/JP2021176893A/ja active Pending
-
2023
- 2023-05-08 US US18/144,695 patent/US20240132474A1/en not_active Abandoned
-
2025
- 2025-05-07 US US19/201,790 patent/US20260085059A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019142930A5 (https=) | ||
| JP2019502669A5 (https=) | ||
| RU2441005C2 (ru) | Новые пиразолопиримидины как ингибиторы циклинзависимых киназ | |
| JP2021098740A5 (https=) | ||
| JP2018504429A5 (https=) | ||
| JP2019513694A5 (https=) | ||
| JP2020007311A5 (https=) | ||
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| JP2018508512A5 (https=) | ||
| JP2019516733A5 (https=) | ||
| JP2017008088A5 (https=) | ||
| JP2020503247A5 (https=) | ||
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| JP2020514311A5 (https=) | ||
| JP2010520289A5 (https=) | ||
| JP2014040437A5 (https=) | ||
| JP2016527279A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| JP2021524835A5 (https=) | ||
| JP2016503399A5 (https=) | ||
| JP2019525948A5 (https=) | ||
| JP2018503610A5 (https=) | ||
| JP2017526662A5 (https=) | ||
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2008536853A5 (https=) |